- Home
- ACIU vs FSTR Comparison
ACIU vs FSTR Comparison
Compare ACIU & FSTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- FSTR
- Stock Information
- Founded
- ACIU 2003
- FSTR 1902
- Country
- ACIU Switzerland
- FSTR United States
- Employees
- ACIU N/A
- FSTR N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- FSTR Metal Fabrications
- Sector
- ACIU Health Care
- FSTR Industrials
- Exchange
- ACIU Nasdaq
- FSTR Nasdaq
- Market Cap
- ACIU 332.4M
- FSTR 288.9M
- IPO Year
- ACIU 2016
- FSTR N/A
- Fundamental
- Price
- ACIU $2.68
- FSTR $27.33
- Analyst Decision
- ACIU Strong Buy
- FSTR Hold
- Analyst Count
- ACIU 2
- FSTR 1
- Target Price
- ACIU $12.00
- FSTR $25.00
- AVG Volume (30 Days)
- ACIU 132.5K
- FSTR 40.3K
- Earning Date
- ACIU 11-05-2024
- FSTR 11-07-2024
- Dividend Yield
- ACIU N/A
- FSTR N/A
- EPS Growth
- ACIU N/A
- FSTR N/A
- EPS
- ACIU N/A
- FSTR 3.85
- Revenue
- ACIU $48,505,404.00
- FSTR $537,459,000.00
- Revenue This Year
- ACIU $85.33
- FSTR $0.44
- Revenue Next Year
- ACIU $80.69
- FSTR $7.16
- P/E Ratio
- ACIU N/A
- FSTR $7.10
- Revenue Growth
- ACIU 4097200.00
- FSTR N/A
- 52 Week Low
- ACIU $2.25
- FSTR $14.23
- 52 Week High
- ACIU $5.14
- FSTR $30.77
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- FSTR 53.06
- Support Level
- ACIU $2.62
- FSTR $25.92
- Resistance Level
- ACIU $3.02
- FSTR $27.08
- Average True Range (ATR)
- ACIU 0.15
- FSTR 1.04
- MACD
- ACIU -0.05
- FSTR -0.53
- Stochastic Oscillator
- ACIU 9.52
- FSTR 36.53
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About FSTR L.B. Foster Company
L.B. Foster Co is a us-based firm engaged in the manufacturing, fabrication, and distribution of products and services, especially for the rail, construction, energy, and utility industries. The company operates its business through three segments: Rail Technologies and Services; Precast Concrete Products and Steel Products and Measurement. Its principal business activity involves providing new and used rail, trackwork, and accessories, producing concrete railroad ties, insulated rail joints, power rail, track fasteners, cover boards, and sales of sells and rents steel sheet piling, H-bearing pile, and other piling products for foundation and earth retention requirements. It generates the majority of its revenues from the Rail Technologies and Services segment.